P
Paul J. Orchard
Researcher at University of Minnesota
Publications - 259
Citations - 14759
Paul J. Orchard is an academic researcher from University of Minnesota. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 48, co-authored 229 publications receiving 12985 citations. Previous affiliations of Paul J. Orchard include University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Cerebral X-Linked Adrenoleukodystrophy: The University of Minnesota Hematopoietic Cell Transplantation Experience from 1991 to 2004.
Charles Peters,Lawrence Charnas,Todd E. DeFor,Elsa Shapiro,Satkiran S. Grewal,Paul J. Orchard,S Abel,Norma K.C. Ramsay,Kathryn E. Dusenbery,Daniel J. Loes,Lawrence A. Lockman,William Krivit +11 more
TL;DR: The international HCT experience from 1982 to 1999 for cerebral X-ALD clearly demonstrated that baseline neurologic and neuropsychological function, degree of disability, and neuroradiologic status predicted outcomes following HCT.
Journal ArticleDOI
Mechanisms of Antioxidant Induction with High-Dose N-Acetylcysteine in Childhood Cerebral Adrenoleukodystrophy.
TL;DR: The data suggest that HO-1 is a possible target protein of NAC and a mediator of its cytoprotective effects in these patients, and that NAC exposure significantly increasedHO-1 expression in fibroblasts.
Journal ArticleDOI
Clinical trial of laronidase in Hurler syndrome after hematopoietic cell transplantation.
Lynda E. Polgreen,Lynda E. Polgreen,Troy C. Lund,Elizabeth A. Braunlin,Jakub Tolar,Bradley S. Miller,Ellen B. Fung,Chester B. Whitley,Julie B. Eisengart,Elise F. Northrop,Kyle Rudser,Weston P. Miller,Paul J. Orchard +12 more
TL;DR: Laronidase seemed to improve growth in participants <8 years old, and 6MWT performance in participants without ADA, and given the small number of patients treated in this pilot study, additional study is needed before definitive conclusions can be made.
Journal ArticleDOI
Reduced-Toxicity (BuFlu) Conditioning Is Better Tolerated but Has a Higher Second Transplantation Rate Compared to Myeloablative Conditioning (BuCy) in Children with Inherited Metabolic Disorders
Ashish Gupta,Michael Downey,Ryan Shanley,Cathryn Jennissen,Weston P. Miller,Troy C. Lund,Paul J. Orchard,Angela R. Smith +7 more
TL;DR: Reduced toxicity conditioning leads to lower rates of infections and other transplant related complications, but concerning for higher rate of graft failure in patients with IMDs.
Journal ArticleDOI
Neurocognitive benchmarks following transplant for emerging cerebral adrenoleukodystrophy.
Elizabeth I. Pierpont,David Nascene,Ryan Shanley,Daniel L. Kenney-Jung,Richard S. Ziegler,Weston P. Miller,Ashish Gupta,Troy C. Lund,Paul J. Orchard,Julie B. Eisengart +9 more
TL;DR: Neurocognitive, neuropsychiatric, and MRI change for boys who underwent hematopoietic stem cell transplant (HSCT) at initial stages of demyelination, prior to neurocognitive signs of disease are reported.